Seres Therapeutics Inc (NASDAQ:MCRB) Receives $6.00 Consensus Target Price from Analysts

Seres Therapeutics Inc (NASDAQ:MCRB) has received an average rating of “Buy” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $6.00.

A number of analysts have commented on MCRB shares. BidaskClub raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, March 6th. ValuEngine lowered shares of Seres Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, March 9th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of Seres Therapeutics in a report on Monday.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MCRB. Squarepoint Ops LLC acquired a new position in shares of Seres Therapeutics in the 3rd quarter valued at $215,000. California State Teachers Retirement System grew its holdings in shares of Seres Therapeutics by 72.3% in the 3rd quarter. California State Teachers Retirement System now owns 56,844 shares of the biotechnology company’s stock valued at $228,000 after buying an additional 23,862 shares during the period. Voya Investment Management LLC grew its holdings in shares of Seres Therapeutics by 35.1% in the 3rd quarter. Voya Investment Management LLC now owns 13,670 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 3,555 shares during the period. Barclays PLC grew its holdings in shares of Seres Therapeutics by 85.1% in the 4th quarter. Barclays PLC now owns 36,539 shares of the biotechnology company’s stock valued at $126,000 after buying an additional 16,802 shares during the period. Finally, KBC Group NV grew its holdings in shares of Seres Therapeutics by 7,603.7% in the 4th quarter. KBC Group NV now owns 10,400 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 10,265 shares during the period. 92.78% of the stock is owned by hedge funds and other institutional investors.

MCRB traded up $0.07 during trading on Monday, reaching $3.50. 259,747 shares of the company’s stock were exchanged, compared to its average volume of 260,744. The company’s fifty day moving average price is $3.39 and its 200-day moving average price is $3.57. Seres Therapeutics has a fifty-two week low of $2.02 and a fifty-two week high of $7.39. The firm has a market capitalization of $249.03 million, a PE ratio of -2.67 and a beta of 1.60.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Monday, March 2nd. The biotechnology company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.03. The business had revenue of $7.62 million for the quarter, compared to analyst estimates of $6.82 million. Equities research analysts forecast that Seres Therapeutics will post -1.01 earnings per share for the current year.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Further Reading: Insider Trading – What You Need to Know

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit